New Horizons in Dyslipidemia Management in Primary Care
|
|
- Roger Eaton
- 6 years ago
- Views:
Transcription
1 New Horizons in Dyslipidemia Management in Primary Care
2 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical, including photocopying, recording, or information storage and retrieval systems without prior written permission of Sea Courses Inc. except where permitted by law. Sea Courses is not responsible for any speaker or participant s statements, materials, acts or omissions.
3 Presenter Disclosure Presenter Peter Lin, MD Optimal control of dyslipidemia in Relationships with commercial interests: patients with CVD Grants/Research Support: N/A Speakers Bureau/Honoraria: AstraZeneca, BMS, Takeda, Purdue, Boehringer Ingelheim, Bayer, Lilly, Amgen, Janssen, Forest Laboratories, J&J, Merck, Novartis, Pfizer, Servier, Sanofi, Abbott, Mylan Consulting Fees: AstraZeneca, Boerhinger Ingelheim, Bayer, Lilly, Merck, Sanofi, Amgen Other: N/A
4 Learning Objectives Upon completion of this activity, participants will be able to: Discuss the role of LDL-C lowering in cardiovascular risk reduction with emphasis on the results of recently completed clinical trials Evaluate recommendations for lipid lowering agents beyond or in addition to statin therapy for patients with atherosclerotic cardiovascular disease Explain the mechanism of action of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and apply the latest clinical data to patient management strategies Apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics
5 Blood Pressure Clot Cholesterol
6 History of Statin Development 70 s Dr. Akira Endo - Sankyo 70 s drug companies focus on antibiotics 1971 Funghi research project started ML 236 B potent inhibitor of HMG Co A reductase
7 Searching for more patients to protect with Statins HeFH MI Stroke PAD
8 Percent with CHD event Where did we get our LDL-C Targets? 4S-Pl 25 Rx - Drug group Pl - Placebo group HPS-Rx CARE-Rx 4S-Rx Lipid-Pl CARE-Pl HPS-Pl LIPID-Rx 5 Target LDL-C 2.5 (100 mg/dl) 0 End of study LDL-C mmol/l (50) (70) (90) (110)(130)(150)(170)(190)(210) (mg/dl) 2.5 (100) Adapted from Kastelein JJ. Atherosclerosis 1999;143(Suppl 1):S17 S21 Heart Protection Study Collaborative Group. Lancet 2002;360:7 22
9 Percent with CHD event Where did we get our LDL-C Targets? 4S-Pl 25 A 10mg Rx - Drug group Pl - Placebo group A 80mg HPS-Rx CARE-Rx 4S-Rx Lipid-Pl CARE-Pl HPS-Pl LIPID-Rx 5 Target LDL-C 1.8 (70 mg/dl) 0 End of study LDL-C mmol/l (50) (70) (90) (110)(130)(150)(170)(190)(210) (mg/dl) 1.8 (70) Adapted from Kastelein JJ. Atherosclerosis 1999;143(Suppl 1):S17 S21 Heart Protection Study Collaborative Group. Lancet 2002;360:7 22
10 Proportion of patients experiencing major CV event Residual Risk HR = 0.78 (95% CI 0.69, 0.89) P= atorvastatin 10 mg atorvastatin 80 mg Residual Risk Time (years) *CHD death, nonfatal non procedure-related MI, resuscitated cardiac arrest, fatal or nonfatal stroke LaRosa JC, et al. N Engl J Med. 2005;352:
11 Residual Risk
12 In Serum the Presence LDL-Cholesterol of PCSK9, Binds the to LDL-Receptors. Is Degraded Following and Does Not Cycle Internalization, Back to Cell LDL Surface is Degraded and the Receptor Recycled LDL Plasma PCSK9 LDL LDL-R LDL-R Endocytosis Hepatocyte Endocytosis Endosome PCSK9 Self-procession LDL-R Recycling Endosome LDL Degradation LDL, LDL-R and PCSK9 Degradation Nucleus Golgi Apparatus Endoplasmic Reticulum (ER) 2013 Amgen Canada Inc. All rights reserved. Qian YW, et al. J Lipid Res. 2007;48: ; Horton JD, et al. J Lipid Res. 2009;50(suppl):S172-S177.
13 Distribution of Plasma LDL Cholesterol Levels (Panel A) and Incidence of Coronary Heart Disease (Panel B) among Black Subjects, According to the Presence or Absence of a PCSK9 142X or PCSK9 679X Allele Cohen, J. et al. N Engl J Med 2006;354:
14 PCSK9 Inhibitors: Targeted Therapy Blocking Monoclonal PCSK9 Antibody Activity binds Inhibits to PCSK9 and inhibits Binding to the Intracellular LDL-Receptor Degradation of LDL-R PCSK9 mab Plasma LDL LDL-R Recycling LDL-R Endocytosis Hepatocyte Endosome PCSK9 Self-procession Lysosome LDL Degradation Nucleus Golgi Apparatus Endoplasmic Reticulum (ER) 2013 Amgen Canada Inc. All rights reserved. Qian YW, et al. J Lipid Res. 2007;48: ; Horton JD, et al. J Lipid Res. 2009;50(suppl):S172-S177.
15 Even Maximal Statin Therapy May Not Be Sufficient In Achieving LDL-C Target 0% 10% 20% 30% 40% 50% 60% Rosuvastatin 10 5 mg 20 mg 10 mg 20 mg 40 mg Atorvastatin 10 mg 20 mg 40 mg 80 mg Simvastatin 10 mg 20 mg 40 mg Pravastatin 10 mg 20 mg 40 mg Doubling the statin dose results in only 6% LDL-C reduction Lovastatin 20 mg 40 mg 80 mg Fluvastatin 20 mg 40 mg *As per Canadian Product Monographs 1. Crestor (rosuvastatin) Product Monograph. AstraZeneca. April 21, Lipitor (atorvastatin) Product Monograph. Pfizer. Feb 18, Pravachol (pravastatin) Product Monograph Bristol-Myers Squibb Canada. Nov 30, Mevacor (lovastatin) Product Monograph. Merck. Jul. 24, Zocor (simvastatin) Product Monograph. Merck. Dec 10, Lescol (fluvastatin) Product Monograph. Novartis. Aug. 26, Adapted from CURVES Investigators. Am J Cardiol. 1998;81:
16 Statin Influence on LDL-C Metabolism plus LDL-R and PCSK9 Acetyl-CoA + acetoacetyl-coa HMG-CoA reductase STATIN PCSK9 Secretion Plasma HMG-CoA LDL Intracellular Cholesterol Biosynthesis LDL-R LDL Protein at Cell Surface PCSK9 Protein Hepatocyte Cholesterol Content Hepatocyte LDL-R Expression PCSK9 Expression SREBP Activation Nucleus Endoplasmic Reticulum (ER)
17 PCSK9 (mg/ml) PCSK9 and Statin Therapy 75 * Baseline Placebo Endpoint Baseline Endpoint Atorvastatin 40 mg * P < 0.05 versus baseline and placebo baseline and endpoint 1. Amgen, data on file. 2. Careskey HE, Davis RA, et al. J Lipid Res. 2008;49: This mechanism may explain the limitation in LDL lowering by statins and why doubling the dose, only results in 6% further LDL reduction
18 Change in LDL-C from baseline (%) LDL-C Efficacy Across the Dose Range The STELLAR Study 0 Dose, mg (log scale) X Rosuvastatin Atorvastatin Simvastatin Pravastatin 30 X n=485 X 40 X * n=473 X n=648 n=634 *p<0.002 vs atorvastatin 10 mg; simvastatin 10, 20, 40 mg; pravastatin 10, 20, 40 mg p<0.002 vs atorvastatin 20, 40 mg; simvastatin 20, 40, 80 mg; pravastatin 20, 40 mg p<0.002 vs atorvastatin 40 mg; simvastatin 40, 80 mg; pravastatin 40 mg Adapted from Jones P et al. Am J Cardiol 2003; 92:
19 Change in LDL-C from baseline (%) LDL-C Efficacy Across the Dose Range The STELLAR Study 0 Dose, mg (log scale) X Rosuvastatin Atorvastatin Simvastatin Pravastatin 30 8 X * n=473 n=634 *p<0.002 vs atorvastatin 10 mg; simvastatin 10, 20, 40 mg; pravastatin 10, 20, 40 mg p<0.002 vs atorvastatin 20, 40 mg; simvastatin 20, 40, 80 mg; pravastatin 20, 40 mg p<0.002 vs atorvastatin 40 mg; simvastatin 40, 80 mg; pravastatin 40 mg Adapted from Jones P et al. Am J Cardiol 2003; 92:
20 PROFICIO (Latin): To advance ;To make progress Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different Populations
21 Evolocumab Clinical Program: PROFICIO Reduce LDL-C (FH, ASCVD, Intolerant) Atherosclerosis CV Events
22 PROFICIO Addresses Key Scientific Questions for Evolocumab Question Description Study What is the safety/efficacy of evolocumab alone? What is the safety/efficacy with statins? Does AMG 145 work in patients with LDLR mutations? Does AMG 145 work in patients with mutations in both LDLR alleles? What is the safety/efficacy in statinintolerant patients? What is the long-term safety/efficacy? Does LDL-C reduction via evolocumab slow or reverse atherosclerosis? Does LDL-C reduction via evolocumab impact CV outcomes? Combination therapy HoFH/ severe FH Long-term effect CV outcomes LAPLACE-1/-2 TESLA/ TAUSSIG DESCARTES, OSLER-1/-2 FOURIER
23 PROFICIO Addresses Key Scientific Questions for Evolocumab Question Description Study What is the safety/efficacy of evolocumab alone? What is the safety/efficacy with statins? Does AMG 145 work in patients with LDLR mutations? Does AMG 145 work in patients with mutations in both LDLR alleles? What is the safety/efficacy in statinintolerant patients? What is the long-term safety/efficacy? Does LDL-C reduction via evolocumab slow or reverse atherosclerosis? Does LDL-C reduction via evolocumab impact CV outcomes? Monotherapy Combination therapy HeFH HoFH/ severe FH Statinintolerant Long-term effect IVUS CV outcomes
24 PROFICIO Addresses Key Scientific Questions for Evolocumab Question Description Study What is the safety/efficacy of evolocumab alone? What is the safety/efficacy with statins? Does AMG 145 work in patients with LDLR mutations? Does AMG 145 work in patients with mutations in both LDLR alleles? What is the safety/efficacy in statinintolerant patients? What is the long-term safety/efficacy? Does LDL-C reduction via evolocumab slow or reverse atherosclerosis? Does LDL-C reduction via evolocumab impact CV outcomes? Monotherapy Combination therapy HeFH HoFH/ severe FH Statinintolerant Long-term effect IVUS CV outcomes MENDEL-1/-2 LAPLACE-1/-2 RUTHERFORD-1/-2 TESLA/ TAUSSIG GAUSS-1/-2/-3 DESCARTES, OSLER-1/-2 GLAGOV FOURIER
25 Evolocumab Clinical Program: PROFICIO Reduce LDL-C (FH, ASCVD, Intolerant) Atherosclerosis CV Events Fourier Trial
26 Do not copy or distribute Amgen Canada Inc. All rights reserved.
27 An Academic Research Organization of Brigham and Women s Hospital and Harvard Medical School 2.37 mmol/l
28 LDL Cholesterol (mmol/l) FOURIER: Median LDL-C Levels Over Time: All Patients No. at risk Placebo Evolocumab 13,779 13, % mean reduction (95% CI 58-60), P < Absolute reduction: 1.45 mmol/l (95% CI ) Placebo Median 2.38 mmol/l Evolocumab Median 0.78 mmol/l Weeks 13,251 13,151 12,954 12,596 12,311 10,812 6,926 3, ,288 13,144 12,964 12,645 12,359 10,902 6,958 3, LDL-C was significantly reduced in the evolocumab group (median: 0.78 mmol/l) including 42% who achieved levels 0.65 mmol/l vs < 0.1% in the placebo group Data shown are median values with 95% confidence intervals in the two arms; ITT. Sabatine MS, et al. NEJM. [published online ahead of print March 17, 2017]. doi: /NEJMoa
29 Proportion of patients experiencing major cardiovascular event Primary Efficacy Outcome Measure: Major Cardiovascular Events* 0.15 HR = 0.78 (95% CI 0.69, 0.89) P= % 0.10 Atorvastatin 10 mg Atorvastatin 80 mg 8.7 % RRR 22% ARR 2.2% NNT 6 45 Screening Time (years) *CHD death, nonfatal non procedure-related MI, resuscitated cardiac arrest, fatal or nonfatal stroke LaRosa JC, et al. N Eng J Med. 2005;352 29
30 Cumulative Incidence (%) FOURIER: Composite of CV Death, MI, or Stroke No. at Risk Placebo Evolocumab Key Secondary Endpoint Placebo + SOC Evolocumab + SOC Months 13,780 13,449 13,142 12,288 7,944 3, ,784 13,501 13,241 12,456 8,094 3, RRR 22% ARR 2.2% NNT RRR 20 % ARR 2.0 % NNT 3 50 HR 0.80 (95% CI 0.73 to 0.88); P < CV = Cardiovascular; MI = Myocardial infarction; HR = Hazard ratio Sabatine MS, et al. NEJM. [published online ahead of print March 17, 2017]. doi: /NEJMoa
31 FOURIER RRR 20% ARR 2% NNT YEARS TNT 6 YEARS RRR 22% ARR 2.2% NNT 6 45
32 Primary Endpoint ITT Cardiovascular death, MI, documented unstable angina requiring rehospitalization, coronary revascularization ( 30 days), or stroke Simva 34.7% 2742 events EZ/Simva 32.7% 2572 events 6.4% RRR 2% ARR NNT year event rates
33 Do not copy or distribute Amgen Canada Inc. All rights reserved.
34 Proportion alive Total Mortality: 4S 1.00 simvastatin placebo Log rank p= Years since randomisation 6 4S Group. Lancet 1994;344:
35 Mortality No. of patients (%) Atorvastatin 10 mg (n=5006) Atorvastatin 80 mg (n=4995) All-cause mortality 282 (5.6) 284 (5.7) Cardiovascular CHD death Stroke death Hemorrhagic stroke death Noncardiovascular Cancer Trauma Other 155 (3.1) 127 (2.5) 8 (0.2) 2 (0) 127 (2.5) 75 (1.5) 9 (0.2) 43 (0.9) 126 (2.5) 101 (2.0) 7 (0.1) 3 (0.1) 158 (3.2) 85 (1.7) 15 (0.3) 58 (1.2) No single Screening cause of death (by body system, or pathological process) and no single cancer type drove the non-significant difference in all-cause mortality between groups No statistically significant differences were observed between treatment groups for any cause of death LaRosa JC, et al. N Eng J Med. 2005;352 35
36 Mortality (%) Mortality in Statin Secondary Prevention Trials non-cv CV S S20 4S PL CARE P40 CARE PL LIPID P40 LIPID PL HPS S40 HPS PL TNT A80 TNT A10 IDEAL A80 IDEAL S20 Against placebo Statin vs Statin
37 Individual Cardiovascular Endpoints and CVD/MI/Stroke HR Simva* EZ/Simva* p-value All-cause death CVD CHD MI Stroke Ischemic stroke Cor revasc 30d UA CVD/MI/stroke Ezetimibe/Simva Better Simva Better *7-year event rates (%)
38 Fourier Trial
39 Do not copy or distribute Amgen Canada Inc. All rights reserved.
40 An Academic Research Organization of Brigham and Women s Hospital and Harvard Medical School
41 True Atherosclerotic Disease Do not copy or distribute Amgen Canada Inc. All rights reserved.
42 42
43 43
44 Are they all the sme?
45 PCSK9 Inhibitors PCSK9 inhibitors (PCSK9i) Evolocumab Alirocumab Bococizumab PCSK9 = Proprotein Convertase Subtilisin Kexin Type 9
46 Terminology of Monoclonal Antibodies Source (% human protein) Mouse (0% human) Chimeric (65% human) Humanized (> 90% human) Human (100% human) Generic suffix: High -omab -ximab Potential for immunogenicity -zumab -umab Low 1. Weiner LM. J Immunother. 2006;29:1-9; 2. Yang XD, et al. Crit Rev Oncol Hematol. 2001;38:17-23; 3. Lonberg N. Nat Biotechnol. 2005;23: ; 4. Gerber DE. Am Fam Physician. 2008;77:
47 PCSK9 Inhibitors PCSK9 inhibitors (PCSK9i) Evolocumab Alirocumab Bococizumab* * Investigational product, not approved by Health Canada PCSK9 = Proprotein Convertase Subtilisin Kexin Type 9
48
49
50 Anti-PCSK9 Antibodies The detection of anti-drug binding antibody formation is highly dependent on the sensitivity and specificity of the assay. Comparison of the incidence of antibodies to evolocumab with incidence of antibodies to other products may be misleading. FAQ Evolocumab Overall incidence of antievolocumab binding antibodies after at least one dose of evolocumab was 0.3% (13 of 4915) Responses were of low-titer, most were transient No neutralizing antibodies have been detected No impact of binding antibodies on safety, pharmacokinetics, or pharmacodynamics Alirocumab Observed in 4.8% of patients following alirocumab treatment vs. 0.6% of patients in control group Most responses were of low-titer, non-neutralizing, and/or transient higher incidence of local injection site reactions (10.2% vs 5.9% if no antibodies) Neutralizing antibodies were reported in 1.2% of patients treated with alirocumab FDA Briefing Document Praluent (alirocumab) injection June 9, 2015; FDA Briefing Document Evolocumab June 10, 2015.
51 Anti-PCSK9 Antibodies The detection of anti-drug binding antibody formation is highly dependent on the sensitivity and specificity of the assay. Comparison of the incidence of antibodies to evolocumab with incidence of antibodies to other products may be misleading. FAQ Evolocumab Overall incidence of antievolocumab binding antibodies after at least one dose of evolocumab was 0.3% (13 of 4915) Responses were of low-titer, most were transient No neutralizing antibodies have been detected No impact of binding antibodies on safety, pharmacokinetics, or pharmacodynamics Alirocumab Observed in 4.8% of patients following alirocumab treatment vs. 0.6% of patients in control group Most responses were of low-titer, non-neutralizing, and/or transient higher incidence of local injection site reactions (10.2% vs 5.9% if no antibodies) Neutralizing antibodies were reported in 1.2% of patients treated with alirocumab FDA Briefing Document Praluent (alirocumab) injection June 9, 2015; FDA Briefing Document Evolocumab June 10, 2015.
52 Anti-PCSK9 Antibodies The detection of anti-drug binding antibody formation is highly dependent on the sensitivity and specificity of the assay. Comparison of the incidence of antibodies to evolocumab with incidence of antibodies to other products may be misleading. FAQ Evolocumab Overall incidence of antievolocumab binding antibodies after at least one dose of evolocumab was 0.3% (13 of 4915) Responses were of low-titer, most were transient No neutralizing antibodies have been detected No impact of binding antibodies on safety, pharmacokinetics, or pharmacodynamics Alirocumab Observed in 4.8% of patients following alirocumab treatment vs. 0.6% of patients in control group Most responses were of low-titer, non-neutralizing, and/or transient higher incidence of local injection site reactions (10.2% vs 5.9% if no antibodies) Neutralizing antibodies were reported in 1.2% of patients treated with alirocumab FDA Briefing Document Praluent (alirocumab) injection June 9, 2015; FDA Briefing Document Evolocumab June 10, 2015.
53 PCSK9 Inhibitor Ongoing OUTCOME Studies Evolocumab FOURIER Outcome Study (5 yrs), N= Inclusion criteria: High-risk 2º prevention population with LDL-C 1.8 mmol/l or non-hdl 2.6 mmol/l Evolocumab 140mg Q2W or 420mg QM + optimal LLT 1º endpoint: Time to CV death, MI, hospitalization for unstable angina, stroke, or coronary revascularization Alirocumab ODYSSEY Outcomes Outcome Study (64 months), N= Inclusion criteria: Hospitalized for ACS within past 1-12 months LDL 1.8mmol/L Alirocumab 75mg Q2W, up-titrate to 150mg Q2W as needed 1º endpoint: Time to CHD death, any non-fatal MI, fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization ACS: acute coronary syndrome; CHD: coronary heart disease; CV: cardiovascular; LLT: lipid lowering therapy; MI: myocardial infarction clinicaltrials.gov accessed August 31, 2015; Swartz GG, et al. Am Heart J. 2014;168(5):682-9.
54 PCSK9 Inhibitor Ongoing OUTCOME Studies Evolocumab FOURIER Outcome Study (5 yrs), N= Inclusion criteria: High-risk 2º prevention population with LDL-C 1.8 mmol/l or non-hdl 2.6 mmol/l Evolocumab 140mg Q2W or 420mg QM + optimal LLT 1º endpoint: Time to CV death, MI, hospitalization for unstable angina, stroke, or coronary revascularization Alirocumab ODYSSEY Outcomes Outcome Study (64 months), N= Inclusion criteria: Hospitalized for ACS within past 1-12 months LDL 1.8mmol/L Alirocumab 75mg Q2W, up-titrate to 150mg Q2W as needed 1º endpoint: Time to CHD death, any non-fatal MI, fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization ACS: acute coronary syndrome; CHD: coronary heart disease; CV: cardiovascular; LLT: lipid lowering therapy; MI: myocardial infarction clinicaltrials.gov accessed August 31, 2015; Swartz GG, et al. Am Heart J. 2014;168(5):682-9.
55 PCSK9 Inhibitor Ongoing OUTCOME Studies Evolocumab FOURIER Outcome Study (5 yrs), N= Inclusion criteria: High-risk 2º prevention population with LDL-C 1.8 mmol/l or non-hdl 2.6 mmol/l Evolocumab 140mg Q2W or 420mg QM + optimal LLT 1º endpoint: Time to CV death, MI, hospitalization for unstable angina, stroke, or coronary revascularization Alirocumab ODYSSEY Outcomes Outcome Study (64 months), N= Inclusion criteria: Hospitalized for ACS within past 1-12 months LDL 1.8mmol/L Alirocumab 75mg Q2W, up-titrate to 150mg Q2W as needed 1º endpoint: Time to CHD death, any non-fatal MI, fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization ACS: acute coronary syndrome; CHD: coronary heart disease; CV: cardiovascular; LLT: lipid lowering therapy; MI: myocardial infarction clinicaltrials.gov accessed August 31, 2015; Swartz GG, et al. Am Heart J. 2014;168(5):682-9.
56 Distribution of Plasma LDL Cholesterol Levels (Panel A) and Incidence of Coronary Heart Disease (Panel B) among Black Subjects, According to the Presence or Absence of a PCSK9 142X or PCSK9 679X Allele Cohen, J. et al. N Engl J Med 2006;354:
57 Meta-analyses suggest earlier, prolonged exposure to lower LDL-C is associated with greater reduction in the risk of CHD Lower LDL-C Meta-Analysis Sample Size (N) OR (95% CI) p (difference) 1.0 mmol/l Genetic Studies 312, ( ) 8.4x10-19 (38.7 mg/dl) Statin Trials 169, ( ) 0.5 mmol/l Genetic Studies 312, ( ) 8.4x10-19 (19.3 mg/dl) Statin Trials 169, ( ) 0.25 mmol/l Genetic Studies 312, ( ) 8.4x10-19 (9.7 mg/dl) Statin Trials 169, ( ) mmol/l Genetic Studies 312, ( ) 8.4x10-19 (4.8 mg/dl) Statin Trials 169, ( ) CHD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol Ference BA, et al. J Am Coll Cardiol. 2012;60:
58 Meta-analyses suggest earlier, prolonged exposure to lower LDL-C is associated with greater reduction in the risk of CHD Lower LDL-C Meta-Analysis Sample Size (N) OR (95% CI) p (difference) 1.0 mmol/l Genetic Studies 312, ( ) 8.4x10-19 (38.7 mg/dl) Statin Trials 169, ( ) 0.5 mmol/l Genetic Studies 312, ( ) 8.4x10-19 (19.3 mg/dl) Statin Trials 169, ( ) 0.25 mmol/l Genetic Studies 312, ( ) 8.4x10-19 (9.7 mg/dl) Statin Trials 169, ( ) mmol/l Genetic Studies 312, ( ) 8.4x10-19 (4.8 mg/dl) Statin Trials 169, ( ) CHD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol Ference BA, et al. J Am Coll Cardiol. 2012;60:
59
60
61
62
63 53% RRR 1.2% ARR NNT 1 83
64 PCSK9 Inhibitors and Their Current Indications Alirocumab 1 o Adjunct to diet and maximally tolerated statin therapy where additional LDL-C lowering is needed in adults with HeFH Clinical ASCVD Evolocumab 2 o Adjunct to diet and maximally tolerated statin therapy where additional LDL-C lowering is needed in adults with HeFH Clinical ASCVD o Adjunct to diet and other LDL-C lowering therapies in persons 12 years with HoFH who require additional LDL-C lowering ASCVD, atherosclerotic cardiovascular disease; HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; LDL-C, low density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin kexin type Praluent Canadian Product Monograph, April 11, 2016; 2. IRepatha Canadian Product Monograph, June ;
65 PCSK9 Inhibitors and Their Indications Alirocumab 1 Adjunct to diet and maximally tolerated statin therapy where additional LDL-C lowering is needed in adults with HeFH Clinical ASCVD Evolocumab 2 Adjunct to diet and maximally tolerated statin therapy where additional LDL-C lowering is needed in adults with HeFH Clinical ASCVD Adjunct to diet and other LDL-C lowering therapies in persons 12 years with HoFH who require additional LDL-C lowering ASCVD, atherosclerotic cardiovascular disease; HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; LDL-C, low density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin kexin type Praluent Canadian Product Monograph, April 11, 2016; 2. IRepatha Canadian Product Monograph, June ;
66 Recommendations for PCSK9i in FH and ASCVD We suggest the use of PCSK9 inhibitors (evolocumab, alirocumab) to lower LDL-C for patients with heterozygous familial hypercholesterolemia whose LDL-C remains above target despite maximally tolerated statin therapy (Conditional recommendation, moderate quality evidence) We suggest that PCSK9 inhibitors be considered to lower LDL-C for patients with atherosclerotic cardiovascular disease in those not at LDL-C goal despite maximally tolerated statin +/- ezetimibe therapy (Conditional recommendation, moderate quality evidence) We suggest that evolocumab be added to background therapy in patients with homozygous familial hypercholesterolemia and continued if LDL-C lowering is documented (Conditional recommendation, moderate quality evidence) Anderson et al Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult Canadian Journal of Cardiology 2016;32:
67 Then PCSK9 Inhibitors Maximize Statin First
Contemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationHyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine
Hyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine The new england journal of medicine Original Article Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationWhats new in lipid management, and Can your high CV risk patients benefit from a PCSK9i?
Whats new in lipid management, and Can your high CV risk patients benefit from a PCSK9i? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationNew Strategies for Lowering LDL - Are They Really Worth It?
New Strategies for Lowering LDL - Are They Really Worth It? Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of CV Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director,
More informationCholesterol, guidelines, targets and new medications
Cholesterol, guidelines, targets and new medications Alexis Baass MD, MSc, FRCPC, DABCL, FNLA Medical Biochemist and Lipidologist MUHC Clinical Researcher and Lipidologist IRCM Disclaimers Grants/Research
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationPCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH
PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH Presented by: Michael J. Blaha November 16, 2017 1 Financial Disclosures Grants: Amgen Foundation, Aetna Foundation Advisory Boards: Amgen,
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha
More informationNew Approaches to Lower LDL-C
New Approaches to Lower LDL-C CSIM 27 October 2016 Jacques Genest MD Cardiovascular Health Across the Lifespan Program McGill University Health Center Disclosure J. Genest MD 2016 Advisory Board, Speaker
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)
More informationPCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia
: 262-267, 2017 Περίληψη Διάλεξης PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia I. Gouni-Bethold Polyclinic for Endocrinology, Diabetes, and Preventive Medicine University
More informationPCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy
PCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy Sergio Fazio, MD, PhD William and Sonja Connor Professor of Preventive Cardiology Professor of Medicine, Physiology & Pharmacology Director, Center for
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationPCSK9 Inhibitors Current Status
PCSK9 Inhibitors Current Status Ryan T. Whitney, MD FACC Bryan Heart Fall Conference 2015 Disclosures, Conflicts, and Nefarious Connections I own no stock in the companies mentioned in this talk. I am
More informationProblem patients in primary care Patient 4: Peripheral artery disease
Problem patients in primary care Patient 4: Peripheral artery disease Dr Terry McCormack Hambleton Richmond Whitby Clinical Commissioning Group Research Lead 01/05/2014 Delivering clinical research to
More informationAccumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges
ESC 2015 London Accumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges Paul M Ridker, MD, MPH Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center for Cardiovascular
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationEducational Objectives. Disease Trajectories and CVD Risk Reduction. Hypercholesterolemia Support for LDL-C Causality
Educational Objectives At the conclusion of this activity, participants should be able to: Evaluate the extent of residual CVD risk to which ASCVD patients are exposed, and treat additional CVD risk elements
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: September 15, 2017 Repatha Description Repatha
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationClinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Repatha) Reference Number: CP.CPA.269 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: November 30, 2018 Repatha Description Repatha (evolocumab)
More informationPCSK9 Inhibitors Current Status
PCSK9 Inhibitors Current Status Ryan T. Whitney, MD FACC Bryan Heart Spring Conference 2016 Disclosures, Conflicts, and Nefarious Connections I own no stock in the companies mentioned in this talk. I am
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationClinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017
Clinical Policy: (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationCholesterol; what are the future lipid targets?
Cholesterol; what are the future lipid targets? lipidologist out-of-business in 5-10 years? G.Kees Hovingh dept of vascular medicine, Academic Medical Center g.k.hovingh@amc.uva.nl Disclosure - Consultant
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More information2/26/19. Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care. Disclosures. Faculty
Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care Faculty v Karol E. Watson, MD, PhD Professor of Medicine/Cardiology Co-director, UCLA Program in Preventive Cardiology
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationManagement of Dyslipidaemias: PCSK9 Inhibition. Alberico L. Catapano Professor President EAS University of Milano Italy
Management of Dyslipidaemias: PCSK9 Inhibition Alberico L. Catapano Professor President EAS University of Milano Italy Conflict of interest Grants, consulting fees and/or honoraria and delivering lectures
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationS3-13: Lipids: Looking forward to
S3-13: Lipids: Looking forward to 2018 Heart and Stroke Clinical Update 1010-1140 9 Dec 2017 Robert Hegele MD, FRCPC, FACP Distinguished University Professor Endocrinologist, University Hospital Western
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationInvestigator Meeting. Monday, September 12, 2016
Investigator Meeting Monday, September 12, 2016 Principal Investigators Milan Gupta, MD, FRCPC, FACC Associate Clinical Professor of Medicine, McMaster University Brampton, ON Steering Committee David
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationPCSK9 and its Role in LDL Receptor Regulation Muscat, Oman - 9 February 2019
PCSK9 and its Role in LDL Receptor Regulation Muscat, Oman - 9 February 2019 Professor Gilles Lambert, PhD LaboratoireInserm U1188 Universitéde la Réunion Faculté de Médecine Saint Denis de la Réunion,
More informationProprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary
Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization
More informationBeyond HDL: new therapeutic targets
Rome Cardiology Forum 2014 An ESC Update Programme in Cardiology Rome, 29-31 2014 Beyond HDL: new therapeutic targets Marcello Arca, MD Dipartimento di Medicina Interna e Specialità Mediche UOS Centro
More informationCCC Dyslipidemia Lipid lowering/atherosclerosis clinical trials update. November 17 th, 2018
CCC Dyslipidemia Lipid lowering/atherosclerosis clinical trials update November 17 th, 2018 Faculty/Presenter Disclosure Faculty: Rick Ward Relationships with commercial interests: Grants/Research Support:
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationUpdate on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP
Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Professor of Medicine Medical-Director, Preventive Cardiology John Ochsner Heart and Vascular
More informationSubject: Repatha (evolocumab) Original Effective Date: 09/28/2015. Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17
Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015 Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17 Review Date(s): 5/4/2016, 4/17/2017, 7/10/2018 DISCLAIMER This Medical Policy
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationDisclosures. Objectives 2/11/2017
Role of Non-Statin Therapy in CV Risk Reduction James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA,FASPC Clinical Assistant Professor of Medicine NYU School of Medicine NYU Langone Center for Cardiovascular
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationNephrologisches Zentrum Göttingen GbR Priv. Doz. Dr. med. V. Schettler
Therapeutic algorithm for Patients with severe Hypercholesterolemia or isolated Lipoprotein(a)-Hyperlipoproteinemia with progressive cardiovascular disease: PCSK9- Inhibitors, Lipoprotein Apheresis or
More informationEVIDENCE TO DATE EVOLOCUMAB (REPATHA)
and Clinical Outcomes in Patients with Cardiovascular Disease, March 2017 1 CLINICAL QUESTION In patients with atherosclerotic cardiovascular disease and LDL >1.8mmol/L or non-hdl > 2.6mmol/L, how does
More informationTHE CRUCIAL PROBLEM OF ASCVD Can New Therapeutic Options Resolve It? THE CRUCIAL PROBLEM OF ASCVD Can New Therapeutic Options Resolve It?
James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA Lipidology and Cardiovascular Disease Prevention Clinical Assistant Professor of Medicine NYU Medical School and NYU Center for CV Prevention
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationPCSK9 Inhibitors: A View of Clinical Studies
PCSK9 Inhibitors: A View of Clinical Studies Slide deck kindly donated for website use by Professor Raul D. Santos Lipid Clinic InCor-HCFMUSP Sao Paulo, Brazil PCSK9 Inhibitors : A View of Clinical Studies
More informationPCSK9 inhibition across a wide spectrum of patients: One size fits all?
PCSK9 inhibition across a wide spectrum of patients: One size fits all? PACE ESC Barcelona 2017 G.K. Hovingh MD PhD MBA dept of vascular medicine Academic Medical Center the Netherlands g.k.hovingh@amc.uva.nl
More informationClinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPA.169 Effective Date:
Clinical Policy: (Repatha) Reference Number: ERX.SPA.169 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationCharacterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER
Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER Stephen D Wiviott, Robert P Giugliano, David A Morrow, Gaetano M De Ferrari, Basil S Lewis, Kurt Huber, Julia
More informationRepatha (evolocumab) Policy Number: Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019
Repatha (evolocumab) Policy Number: 5.01.601 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Repatha
More informationW J C. World Journal of Cardiology. PCSK9 inhibitors: A new era of lipid lowering therapy. Abstract REVIEW
W J C World Journal of Cardiology Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.4330/wjc.v9.i2.76 World J Cardiol 2017 February 26; 9(2): 76-91 ISSN 1949-8462 (online) REVIEW PCSK9 inhibitors:
More informationPraluent. Praluent (alirocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.06 Subject: Praluent Page: 1 of 10 Last Review Date: September 20, 2018 Praluent Description Praluent
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationStatins and PCSK9 inhibitors for stroke prevention
Statins and PCSK9 inhibitors for stroke prevention Haralampos Milionis Professor of Internal Medicine School of Medicine, University of Ioannina Ioannina, Greece Reduction in CV events (%) Every 1 mmol/l
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Statin Therapy Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Statin Therapy Prime Therapeutics will review Prior Authorization requests. Prior Authorization
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationClinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:
Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationChallenges in lipid management
Challenges in lipid management Milan Gupta MD, FRCPC, FACC State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University of Toronto
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Repatha) Reference Number: HIM.PA.SP46 Effective Date: 01.01.18 Last Review Date: Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationClass Update PCSK9 Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 24 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)
More informationRequest for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax
Request for Prior Authorization for PCSK9 inhibitor therapy Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 PCSK9 is a protein that reduces the hepatic removal of low-density
More informationA New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies
A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies BRODY MAACK, PHARMD, BCACP, CTTS Objectives 1. Review current guidelines regarding use of statin medications in the treatment and prevention
More informationFrom Biology to Therapy The biology of PCSK9 in humans Just LDL-cholesterol or more? May 24th. Dr. Gilles Lambert
Dr. Gilles Lambert Associate Professor in Cell Biology University of Nantes Medical School Group Leader, Laboratory of Nutrition and Metabolism, University Hospital of Nantes From Biology to Therapy The
More informationManaging Lipids and Cardiovascular Risk: Using the Data to Optimize Care
Emerging Challenges in Primary Care: 2018 Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care Faculty Ola Akinboboye, MD, MPH, MBA Associate Professor of Clinical Medicine Cornell
More informationDrug Class Review Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors
Drug Class Review Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors Final Original Report July 2015 The purpose of reports is to make available information regarding the comparative clinical
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationPCSK9 Inhibitors for Lowering Cholesterol: Ready for Prime Time?
Original Article Thomas Knickelbine, MD, FACC, FSCCT, FSCAI From: Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN Address for correspondence: Thomas Knickelbine, MD, FACC,
More informationClass Update PCSK9 Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDrug Prior Authorization Guideline PCSK9 Inhibitors -
Drug Prior Authorization Guideline PCSK9 Inhibitors - REPATHA (evolocumab) PRALUENT (alirocumab) PA9911 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below Additional
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationRandomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study
Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study Michael J Koren 1, Robert P Giugliano 2, Frederick Raal 3, David
More informationClinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017
Clinical Policy: (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More information